Drug/Software Combos Likely Won't Require Pre-Market Review By US FDA

But sponsors should sometimes seek advisory comment. Agency explains that most drug-use-related apps will be considered promotional labeling. FDA seeking feedback from a variety of stakeholders on its discussion proposal for regulating prescription-focused software.

Touch the future,Interface technology, the future of user experience.

The US FDA anticipates that sponsors will generally not need to obtain pre-market approval for the output of prescription drug-use-related software, although the agency is also encouraging they use the voluntary advisory comment process in certain cases.

In officially announcing its discussion proposal in a Federal Registernotice scheduled to be published Nov. 20, FDA recommended drugmakers use the advisory process when "the use of the prescription...

More from Digital Technologies

More from Advanced Technologies